A Phase 1 interventional study of Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Glioblastoma and MGMT-Unmethylated Glioblastoma, sponsored by Basilea Pharmaceutica. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 677th largest by enrollment of the 1,155 interventional ones that give a count, is one of 55 that started in 2017, is one of 481 in phase 1, and was the 803rd registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 55 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 883 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 2 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
104 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 104 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with GBM.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of microtubule-targeted agent BAL101553 (BAL101553) in combination with standard radiation in patients with newly diagnosed MGMT promoter unmethylated GBM.
SECONDARY OBJECTIVES:
I. To estimate safety and tolerability of the combination of BAL101553 in combination with standard radiation in patients with newly diagnosed MGMT promoter unmethylated GBM.
II. To determine overall and progression-free survival.
OUTLINE: This was a dose escalation study of the microtubule-targeted agent BAL101553.
Patients received BAL101553 orally (PO) once daily (QD) for 6 weeks, concurrent with standard radiation therapy (RT) 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
This treatment period was followed by a 4-week no-treatment period. The duration of study treatment was defined as these 6 weeks of treatment plus the 4 weeks of rest.
The safety evaluation period was the 10 weeks from start of treatment
After completion of study treatment, patients were followed up at 30 days, and then every 2 months for 2 years and then every 6 months thereafter.
The following inclusion criteria were applied:
The following exclusion criteria were applied:
Significant cardiac disease or abnormality, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
Drug: Microtubule-Targeted Agent BAL101553 · Radiation: Radiation Therapy
Given PO
Also known as: BAL101553, Microtubule-targeted Agent BAL101553
Undergo radiation therapy
Also known as: Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation, radiation therapy, Radiation Therapy, Radiotherapeutics, radiotherapy, Radiotherapy, RT, Therapy, Radiation
Number of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort
A DLT was defined as a clinically-significant adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications. Any DLT had to be a toxicity considered at least possibly related to BAL101553 or the combination of BAL101553 and radiation.
Time frame: Up to 10 weeks
Number of Patients With Grade 3 to Grade 5 Adverse Events (AEs)
Common Terminology Criteria for Adverse Events (CTCAE) displayed by increasing severity grades 3 to 5 (CTCAE grade 3/4/5 )
Time frame: up to 10 weeks
Overall Survival (OS) Time
OS was defined as the time from Day 1 dosing to the date of death. Patients who have not died at study closure were censored at the time of last known alive.
Time frame: Day 1 to date of death - up to 1679 days (4.6 years)
Progression Free Survival (PFS) Time
PFS was the interval between Day 1 dosing and the earliest date of progression. Progression was defined as: an increase in tumor size of more than 25% or the appearance of new lesions on MRI scans, significant clinical deterioration not attributable to causes other than the tumor, or death from any cause. Patients who have not progressed or died at study closure were censored at the time of their last assessment without progression.
Time frame: Day 1 to date of disease progression - 1092 days (3.0 years)
Treatment was administered on an outpatient basis
| Milestone | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Started | 5 | 0 | 0 | 0 | 0 |
| Completed | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Started | 0 | 5 | 0 | 0 | 0 |
| Completed | 0 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 | 0 |
| Milestone | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Started | 0 | 0 | 7 | 0 | 0 |
| Completed | 0 | 0 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Milestone | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 5 | 0 |
| Completed | 0 | 0 | 0 | 3 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 |
| Milestone | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 4 |
| Completed | 0 | 0 | 0 | 0 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
A DLT was defined as a clinically-significant adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications. Any DLT had to be a toxicity considered at least possibly related to BAL101553 or the combination of BAL101553 and radiation.
| participants | BAL101553 4 mg MTD-determining Cohort | BAL101553 6 mg MTD-determining Cohort | BAL101553 8 mg MTD-determining Cohort | BAL101553 12 mg MTD-determining Cohort | BAL101553 15 mg MTD-determining Cohort |
|---|---|---|---|---|---|
| Number of Patients With Dose-Limiting Toxicities (DLTs) for Each Maximal Tolerated Dose (MTD)-Determining Dose Cohort | 0 | 0 | 1 | 1 | 0 |
Common Terminology Criteria for Adverse Events (CTCAE) displayed by increasing severity grades 3 to 5 (CTCAE grade 3/4/5 )
| Participants | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Number of patients with only unrelated CTCAE Grade 3/4/5 AEs | 1 | 2 | 1 | 2 | 1 |
| Number of patients with related CTCAE Grade 3/4/5 AEs | 1 | 1 | 1 | 1 | 0 |
| Number of patients without CTCAE Grade 3/4/5 AEs | 3 | 2 | 5 | 2 | 3 |
OS was defined as the time from Day 1 dosing to the date of death. Patients who have not died at study closure were censored at the time of last known alive.
| Days | All BAL101553 Treated Patients |
|---|---|
| Overall Survival (OS) Time | 383.0 (273.0 to 552.0) |
PFS was the interval between Day 1 dosing and the earliest date of progression. Progression was defined as: an increase in tumor size of more than 25% or the appearance of new lesions on MRI scans, significant clinical deterioration not attributable to causes other than the tumor, or death from any cause. Patients who have not progressed or died at study closure were censored at the time of their last assessment without progression.
| Days | All BAL101553 Treated Patients |
|---|---|
| Progression Free Survival (PFS) Time | 247.0 (128.0 to 366.0) |
Collected over Adverse events (AEs) were collected for 10 weeks from start of treatment, All-cause Mortality monitored up to 1679 days (4.6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BAL101553 4 mg Cohort | 5/5 (100%) | 2/5 (40%) | 5/5 (100%) |
| BAL101553 6 mg Cohort | 5/5 (100%) | 3/5 (60%) | 5/5 (100%) |
| BAL101553 8 mg Cohort | 4/7 (57.1%) | 2/7 (28.6%) | 7/7 (100%) |
| BAL101553 12 mg Cohort | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| BAL101553 15 mg Cohort | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Event | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/5 | 0/5 | 0/7 | 0/5 | 1/4 |
| SepsisInfections and infestations | 0/5 | 0/5 | 0/7 | 1/5 | 1/4 |
| Urinary tract infectionInfections and infestations | 0/5 | 0/5 | 0/7 | 0/5 | 1/4 |
| AphasiaNervous system disorders | 1/5 | 0/5 | 0/7 | 0/5 | 0/4 |
| Brain oedemaNervous system disorders | 1/5 | 0/5 | 0/7 | 0/5 | 0/4 |
| Cognitive disorderNervous system disorders | 0/5 | 1/5 | 0/7 | 0/5 | 0/4 |
| DysarthriaNervous system disorders | 1/5 | 0/5 | 0/7 | 0/5 | 0/4 |
| Facial paresisNervous system disorders | 1/5 | 0/5 | 0/7 | 0/5 | 0/4 |
| HydrocephalusNervous system disorders | 0/5 | 1/5 | 0/7 | 0/5 | 0/4 |
| LethargyNervous system disorders | 0/5 | 1/5 | 0/7 | 0/5 | 0/4 |
| Event | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort |
|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/5 | 1/5 | 2/7 | 4/5 | 2/4 |
| FatigueGeneral disorders | 4/5 | 4/5 | 5/7 | 3/5 | 3/4 |
| AnaemiaBlood and lymphatic system disorders | 1/5 | 1/5 | 3/7 | 1/5 | 3/4 |
| Aspartate aminotransferase increasedInvestigations | 0/5 | 0/5 | 1/7 | 3/5 | 1/4 |
| HeadacheNervous system disorders | 0/5 | 3/5 | 3/7 | 0/5 | 0/4 |
| NauseaGastrointestinal disorders | 3/5 | 2/5 | 3/7 | 1/5 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/5 | 3/5 | 3/7 | 1/5 | 1/4 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/5 | 2/5 | 0/7 | 3/5 | 1/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/5 | 3/5 | 1/7 | 3/5 | 0/4 |
| HyponatraemiaMetabolism and nutrition disorders | 0/5 | 3/5 | 4/7 | 3/5 | 0/4 |
| Age, Categorical(Participants) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 2 | 5 | 2 | 2 | 14 |
| >=65 years | 2 | 3 | 2 | 3 | 2 | 12 |
| Age, Continuous(years) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| Mean | 58.2 ± 10.57 | 67.6 ± 6.27 | 57.7 ± 11.22 | 62.6 ± 12.10 | 57.8 ± 13.40 | 60.7 ± 10.71 |
| Sex: Female, Male(Participants) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 2 | 4 | 3 | 2 | 15 |
| Male | 1 | 3 | 3 | 2 | 2 | 11 |
| Ethnicity (NIH/OMB)(Participants) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 3 | 6 | 5 | 4 | 23 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 1 |
| White | 5 | 5 | 6 | 4 | 3 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | BAL101553 4 mg Cohort | BAL101553 6 mg Cohort | BAL101553 8 mg Cohort | BAL101553 12 mg Cohort | BAL101553 15 mg Cohort | Total |
|---|---|---|---|---|---|---|
| United States | 5 | 5 | 7 | 5 | 4 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jun 2022, 53 months.
Results were first posted in Jun 2024, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisavanbulin